Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04616326 · ClinicalTrials.gov registry record · Phase 3
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
A Phase 3 study of Chronic Migraine, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
- 20
- Study locations
NCT04616326: Active Phase 3 study of Chronic Migraine, sponsored by Eli Lilly and Company.
NCT04616326 is a Phase 3 study of Chronic Migraine that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 312 participants, roughly in line with the 325-participant average among 17 other Chronic Migraine trials with a reported enrollment target. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04616326, a Phase 3 study of Chronic Migraine, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Primary Outcome
Change from Baseline in the Number of Monthly Migraine Headache Days
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Galcanezumab
Study Locations (20)
Florida
- Northwest Florida Clinical Research Group - Gulf Breeze
- Clinical Neuroscience Solutions, Inc. dba CNS Healthcare - Jacksonville
- Vitaly Clinical Research - Miami
- EMDA Clinical Research - Miami
- Bio-Medical Research LLC - Miami
- Allied Biomedical Research Institute - Miami
- Ezy Medical Research - Miami Lakes
- Wellness Clinical Research - Miami Lakes
- Avanza Medical Research Center - Pensacola
- D&H Tamarac Research Center - Tamarac
- Infinity Life Research Group - Tamarac
- USF Health - Tampa
- Palm Beach Research Center - West Palm Beach
Arizona
- 21st Century Neurology, a Division of Xenoscience, Inc. - Phoenix
- Phoenix Children's Hospital - Phoenix
- Center for Neurosciences - Tucson
Alabama
- Rehabilitation & Neurological Services - Huntsville
California
- Miller Children's & Women's Hospital Long Beach - Long Beach
Colorado
- Children's Hospital Colorado - Aurora
Idaho
- Medical Research Partners - Ammon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2020-11-25 |
| Est. Completion | 2027-03 |
| Phase | Phase 3 |
What the registry record for NCT04616326 still lists
NCT04616326 is an interventional study that assigns participants to a tested intervention. The registered 312 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 325-participant average among 17 other Chronic Migraine trials with a reported enrollment target.
The record links to 1 condition, with Chronic Migraine appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04616326 names 20 study sites across 6 states, led by Florida, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT04616326 about?
NCT04616326 is a clinical study titled "A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine". The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine he...
What is the current status of trial NCT04616326?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2020-11-25. Estimated completion is 2027-03.
What conditions does trial NCT04616326 study?
This clinical trial studies the following conditions: Chronic Migraine.
What interventions are being tested in trial NCT04616326?
The interventions under investigation include: Placebo (DRUG), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT04616326?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04616326 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04616326's enrollment target sits among peer trials
312 8th of 17 higher than 10 of 17 other Chronic Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOTOX® vs. XEOMIN® for Chronic Migraine
RECRUITING · Phase 3
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
RECRUITING · Phase 3
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
RECRUITING · Phase 3
-
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
ACTIVE NOT RECRUITING · Phase 3
-
Responding With Evidence and Access for Childhood Headaches
RECRUITING · NA
-
Determining the Utility of a Behavioral Intervention in Chronic Migraine
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04984551 · 312 participants · Phase 2
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
- NCT04999904 · 312 participants · NA
A Proprioceptive Training Program Using an Uneven Terrain Treadmill for Patients With Ankle Instability
- NCT05220332 · 312 participants · NA
Church-based Intervention to Improve Blood Pressure in African Americans
- NCT05434234 · 312 participants · Phase 1
A Study of YL201 in Patients With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI